vs
Side-by-side financial comparison of ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) and NOVO NORDISK A S (NVO). Click either name above to swap in a different company.
Ascentage Pharma Group International is a global clinical-stage biotechnology company specializing in developing novel targeted therapies for cancers, chronic viral infections, and age-related diseases. It focuses on small molecule drugs targeting apoptosis pathways and other key oncogenic mechanisms, with operations spanning China, the U.S., and other global markets, serving patients with unmet medical needs worldwide.
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $574.1K | — | ||
| Q2 25 | $32.6M | — |
| Q4 25 | — | — | ||
| Q2 25 | $11.4M | — |
| Q4 25 | — | — | ||
| Q2 25 | 90.7% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
